利奈唑胺治疗颅内感染25例临床分析.docVIP

利奈唑胺治疗颅内感染25例临床分析 王宁* 郭芳 李佰涛 战华 孟祥喜 齐春晓 李中振 李国夫 *：为通讯作者ningwsfm@ 【摘 要】目的:初步评价利奈唑胺注射液治疗颅内感染的临床疗效和安全性。方法：回顾性分析和总结我们医疗组2009年3月-2012年11月治疗的25例神经外科疾病术后并发颅内感染患者的情况。结果:25例患者在应用利奈唑胺治疗1-3天后，感染症状开始缓解；出院时，全部患者体温恢复正常，23例脑脊液常规恢复正常，其中20例脑脊液培养无细菌生长，2例拒绝腰穿患者血常规正常。全部患者应用利奈唑胺均未出现不良反应。结论:利奈唑胺可有效治疗G+球菌（包括MRSA）所致颅内感染，临床安全性好。 【关键词】 颅内感染；利奈唑胺；G+球菌；MRSA. Clinical analysis of Linezolid on treatment of 25 patients with intracranial infection. Wang Ning , Guo Fang ,Li Baitao , et al.Department of neurosurgery The First Affiliated Hospital of Harbin Medical University ,Harbin 150001 【Abstract】Objective:To evaluate the clinical efficacy and safety of Linezolid injection treatment for the patients with intracranial infection. Methods: Twenty five patients with intracranial infection from March 2009 to november 2012 were enrolled. Results: After 1-3 days of treatment with Linezolid ,the symptoms of inflammation in twenty-five patients were in part relieved. To discharge, the body temperatures of twenty-five patients and the results of cerebrospinal fluid routine examinations of twenty-three patients were normal, and there was no bacteria in CSF cultures of twenty patients. Two cases refused lumbar puncture ,and their blood routine examinations were normal. No adverse events were found from these patients. Conclusion: Linezolid was effective for the treatment of patients with intracranial infection caused by G+ cocci（including MRSA） with a high clinical safety. 【Key words】intracranial infection；Linezolid；G+ coccus；MRSA. 2000年，利奈唑胺获得美国FDA批准在美国首次上市，对革兰氏阳性球菌有很强的抑菌作用，可强效覆盖葡萄球菌，MRSA，MSSA，凝固酶阴性葡萄球菌，表皮葡萄球菌和粪肠球菌等[1]，主要应用于肺感染和皮肤软组织感染，其对颅内感染的疗效和安全性国内外少有报道。本文回顾性分析和总结我们医疗组应用利奈唑胺治疗25例（为目前国内外相关文献报告中例数最多者）颅内感染患者的情况，初步评价利奈唑胺治疗颅内感染的临床疗效和安全性，报告如下: 1.临床资料 1.1 一般资料 收集我科2009年3月-2012年11月使用利奈唑胺治疗的25例颅脑病变术后并发颅内感染的住院患者，其中男11例，女14例，年龄31-76岁，平均53.83岁。其中23例在我院行手术治疗，2例为外院术后颅内感染转入我院。 1.2 原发病 高血压脑出血5例，听